• news.cision.com/
  • Brighter AB (publ)/
  • The Nomination Committee's proposal to the Board prior to the 2022 Annual General Meeting includes a key player in the diabetes market

The Nomination Committee's proposal to the Board prior to the 2022 Annual General Meeting includes a key player in the diabetes market

Report this content

The Nomination Committee of Brighter AB (publ) proposes Johnny Ludvigsson, one of the world's top ten experts and researchers on type 1 diabetes, as a new board member of Brighter AB.

Johnny Ludvigsson is a Swedish doctor and professor of pediatrics at Linköping University, chief physician at the Children and Women's Center at the University Hospital in Linköping and founder of the Child Diabetes Foundation. With his worldwide network of contacts and extensive experience and expertise, Ludvigsson is expected to be a significant asset for Brighter in its continued work to create solutions for connected and data-driven diabetes care.

“The number of people suffering from diabetes is increasing every year and the treatment of diabetes-related diseases also entails large costs for global healthcare. I look forward to working with Brighter and their digital solutions that strive to make it easier for both patients and healthcare” says Johnny Ludvigsson.

Brief information about Johnny Ludvigsson, new proposed board member:
In the years 1985-1991, Johnny Ludvigsson was Secretary General of the International Society for Pediatric and Adolescent Diabetes, the world organization for childhood and adolescent diabetes. He has received, among other things, the Novo Nordisk Foundation's award for diabetes research in 1998 and the Inaugural ISPAD Prize in 2001, and has been appointed an Honorary Member of EASD, Honorary Member of ISPAD, and an honorary member of the Swedish Diabetes Association. Ludvigsson was named Diabetologist of the Year in 2009, and in 2014 he was awarded the Knud Lundbæck Award by the Scandinavian Society for the Study of Diabetes. To date, he has published more than 500 articles, and every year the Child Diabetes Foundation awards two prizes in Johnny Ludvigsson's name to prominent child diabetes researchers in the Nordic countries and in Sweden.

The Nomination Committees proposal
Besides the proposal of Johnny Ludvigsson as new board member, the Nomination Committee of Brighter AB also proposes re-election of the Board members Åsa Sjöblom Nordgren, Karin O’Connor and Clas Lindbergson. Hab El Assaad's tenure on Brighter's Board of Directors ends, at his own request, in connection with the Annual General Meeting and he is therefore not a candidate for re-election. Brighter looks forward to arrangements for continued benefit from Hab El Assaad’s expertise in furthering the company’s strategy and execution. Furthermore, it is proposed to re-elect Christer Trägårdh as Chairman of the Board.

Information on all existing proposed members for re-election can be found on Brighter's website (www.brighter.se).

The Nomination Committee consists of Staffan Hægermark, Nino Armoni, Jimmy Tiljander and Christer Trägårdh, Chairman of the Board of Brighter AB. Staffan Hægermark is the chairman of the nomination committee.
The Annual General Meeting will be tentatively held on May 5, 2022, at the head office in Kista.

For more information, please contact:

Investor Relations

Chairman of the Election Committee
Staffan Hægermark
Mobile +46 (0)76-525 38 30

Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10:30 CET on February 9 2022.

About Brighter
Brighter is a health-tech Company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO13485 certified. In 2019 the Company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

For more information, please visit our website at www.brighter.se

Documents & Links